Skip to content
Peptide Evidence Registry

Longevity

Epitalon

Longevity claims built on an old, narrow and largely unreplicated body of research.

L1Theory onlyResearch / unapproved supplyPreclinical
How settled this rating is:
very-low confidence in the current evidence rating
Routes studied:
Not established · Subcutaneous injection, Nasal (marketed but never approved)
Also known as:
epithalon, AEDG peptide
Last reviewed:
2026-08-23
Jump to section

Evidence passport

Epitalon

A one-screen evidence identity for this compound. These fields describe research maturity, confidence and legal status. They are not a safety guarantee, efficacy percentage or recommendation.

Reviewed 2026-08-23
Evidence level
L1Theory only
Confidence
Very low confidence in rating
Regulatory status
Research / unapproved supply
Development status
Preclinical

Evidence strength

Human efficacy evidence10 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Human safety evidence10 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

The 0-100 values rate the strength and maturity of evidence, not how effective or safe the compound is.

Evidence base
Mostly animal and laboratory research
Furthest established stage
Not established
Human research maturity
Preclinical and historical small-scale human reports
Source curation
Sources fully curated

Routes recorded

SC injection· unapprovedNasal· unapproved

Most of this evidence comes from animals and cells

The supporting research for Epitalon is predominantly preclinical (Level 1–2). That is a legitimate starting point for science and a poor basis for personal decisions. Human results are not simply a scaled-up version of mouse results.

Overview

Human efficacy evidence strength10 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Preclinical (animal / lab) evidence strength45 of 100 evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Human safety evidence strength10 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

How far human research has progressed: Preclinical and historical small-scale human reports

Routes & formulations

Marketed / research routes — never approved

SC injection· unapprovedNasal· unapproved

No approved formulation exists. Research-market material is typically injectable or nasal; no route has controlled human evidence behind it.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

PreclinicalFurthest stage not established in our curated record

Historical small-scale human reports exist, but no modern clinical development programme is established.

What it is

A synthetic four-amino-acid peptide derived from a pineal gland extract, promoted for telomere maintenance and lifespan extension.

What people claim

  • Lengthens telomeres
  • Extends human lifespan
  • Restores pineal and circadian function

What the evidence actually says

Most of the supporting literature comes from a narrow historical research tradition, with limited independent replication and methods that would not meet modern standards. Telomerase activation in cell culture is a long way from a longer human life. Human lifespan extension is unproven.

Related evidence

Useful next reads based on this compound — not recommendations.

Human evidence

  • Historical small-scale human reports with significant methodological limitations and little independent replication.
  • No modern randomised controlled trials.

Preclinical evidence

  • Cell studies reporting telomerase activation in fibroblast cultures.
  • Rodent studies from a limited research network reporting lifespan or tumour-incidence effects.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Proposed activation of telomerase and telomere maintenance.
  • Proposed modulation of pineal melatonin signalling and circadian rhythm.

Safety and unknowns

  • No meaningful modern human safety data.
  • Chronic telomerase activation has theoretical implications that have not been studied in humans.

Cancer relevance

This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.

Theoretical / mechanistic concern only

Telomerase reactivation is a hallmark of many cancers, so deliberately activating it is a legitimate theoretical concern. There is no human evidence that Epitalon causes cancer — and no human evidence that it does not. Unknown is the accurate word.

Regulatory status

Regulatory decisions apply to specific jurisdictions, products, formulations and indications. An approval elsewhere is not automatically an approval in your country.

Check the regulatory note and linked primary sources for jurisdiction-specific details.

Not an approved medicine in major regions. Sold as a research compound. FDA has treated epitalon as a bulk substance raising significant safety risks for compounding; that listing status changed during 2026 and it was covered by FDA's July 2026 advisory committee review.

Evidence grade

L1Theory onlyVery low confidence in rating

Mechanistic rationale or early development without qualifying compound-specific outcome evidence. A registered trial is not a result.

What would change our rating?

  • Independent replication of telomere effects with modern measurement methods.
  • Any registered randomised controlled trial with objective endpoints.

References and sources

Source transparency

A provenance snapshot of this profile. Counts show what kinds of sources are cited, not how much scientific weight each source deserves.

Sources fully curated
Last editorial review
2026-08-23
Recently reviewed · 54 days ago
Linked curated sources
3
Sources still pending
0
External specialist reviews
0
None recorded for this profile
Regulatory / label: 3

Review provenance

Registry editorial review: Colin Jackson-White, creator and editor, who is not a doctor or clinician. External specialist review is credited only when a named reviewer has completed a review of this exact profile.

Literature-discovery and AI tools may help locate or challenge candidate evidence, but they are not counted as evidence sources here. Registry judgements are tied to the underlying papers, trial records, regulator documents and official study records.

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

These entries record changes to our assessment of the published evidence — not changes to the compound itself.

  1. Baseline entry: lifespan-extension claims recorded as unsupported.

    Change 1 of 1
    L1Theory onlyBaseline entry
    Supporting literature is historical, narrow and largely unreplicated. Mechanistic telomerase findings do not establish human outcomes.

Related claims we’ve checked — in full

Claim verdict

Longevity

Not supported as wordedL1Theory only

“Epitalon extends human lifespan.”

This verdict applies to the exact claim above. It is not a verdict on the compound overall, a safety guarantee, or a recommendation to use it.

Registry verdict

Unsupported — human lifespan extension has never been demonstrated for any peptide.

Why this verdict

  • The supporting literature is old, narrow and largely unreplicated independently.
  • Telomerase activation in cell culture is mechanistic evidence, not a lifespan outcome.
  • Human lifespan trials are extraordinarily hard to run, which is precisely why nobody should claim to have won one.